NURIX THERAPEUTICS, INC.: cashflow_financing
| Value | {"amount": 1488000, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2021-12-01 – 2022-02-28 |
| Status | current |
| Entity | NURIX THERAPEUTICS, INC. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T15:43:20.797219+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/bb7d3489-d3c1-4f7e-98f9-535347490200
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001564590-22-013988 · Open the official SEC filing →Retrieved: 2026-08-19T15:43:20.797219+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001549595/cashflow-financing/2022-02-28 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/bb7d3489-d3c1-4f7e-98f9-535347490200
History
- no predecessors — first report